ClinicalTrials.gg

Program

sevoloprubart

Its studies are mostly in Multiple Sclerosis · Arthritis, Rheumatoid, led by Eli Lilly.

Furthest: phase 2, since Jan 15, 20243 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly30 open or runningphase 2since Jan 15, 2024Sep 8, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2021First study: phase 1 study in HealthyFirst studyNCT05042310 · 94 enrolled · Japan
  2. Jan 15, 2024Phase 2 study in Multiple SclerosisNCT06220669 · 65 enrolled · United States, France, Italy and more
  3. Feb 28, 2025Phase 2 study in Arthritis, RheumatoidNCT06859294 · 35 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06859294Arthritis, Rheumatoid · United States2TerminatedNov 10, 202535
NCT06220669Multiple Sclerosis · United States, France, Italy and more2TerminatedOct 18, 202565
NCT05042310Healthy · Japan1CompletedDec 27, 202394

How it is read

Names in the registry

  • “LY3541860”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.